Insmed Incorporated
Biopharma selling rare-disease drugs, including new bronchiectasis treatment BRINSUPRI and lung-infection drug ARIKAYCE.
On the record
Checkpoint: Q2/Q3 2026 earnings will show whether BRINSUPRI demand keeps growing or was inflated by one-time patient assistance starts
The call
Insmed's near-term story rests on whether BRINSUPRI's early patient surge turns into steady organic growth, not on any AI or Big Pharma threat.
Insmed sells two approved medicines for hard-to-treat lung infections: BRINSUPRI (its newest drug for a type of bronchiectasis) and ARIKAYCE (for a related condition). These drugs are legally protected for several years because the FDA approved them first and gave them orphan-drug status, which means AstraZeneca, Vertex, and other big drug makers cannot copy them right now, and artificial intelligence cannot bypass the regulatory approval process needed to sell a new medicine. The key question is whether patients will keep using BRINSUPRI at the rate Insmed expects in the second half of 2026, since the first quarter's sales numbers may have included a rush of patients seeking early access, which could artificially inflate growth and hide slower real demand.
Why
01
AI pressure: None apparent. AI can speed up drug discovery elsewhere but cannot copy an FDA-approved molecule or its patent protection. Could AI do the core job? Unlikely.
02
Bigger players: Verona Pharma (ensifentrine). Verona's ensifentrine is in earlier-stage bronchiectasis trials and could challenge BRINSUPRI's position if its data reads out well. Could a giant copy it? No, they are blocked.
03
What protects it. FDA/EMA/MHRA approval plus first-in-class status for BRINSUPRI blocks direct copies for years, and cash reserves cover the runway.
What would change this call
Insmed reports Q2/Q3 2026 BRINSUPRI revenue and net-new patient start counts. Shows whether demand is organic growth or a pull-forward air-pocket from Right-to-Try patients.
Verona Pharma reports ensifentrine Phase 2 non-CF bronchiectasis data and any approval progress. Would show a rival drug reaching the market to compete directly with BRINSUPRI.
Insmed's Phase 3 TPIP (PALM-PAH) trial initiation and later readout by end of 2026. Failure would remove a key pipeline asset investors are counting on beyond BRINSUPRI.
Verona Pharma reports ensifentrine Phase 2 non-CF bronchiectasis data and any approval progress. Would show a rival drug reaching the market to compete directly with BRINSUPRI.
Insmed's Phase 3 TPIP (PALM-PAH) trial initiation and later readout by end of 2026. Failure would remove a key pipeline asset investors are counting on beyond BRINSUPRI.
Key numbers
- BRINSUPRI Q1 2026 revenue $207.9M, up 44% QoQ
- ARIKAYCE Q1 2026 revenue $98.1M, up 6% YoY
- Cash and securities about $1.2B
Named risks
- BRINSUPRI Q1 2026 demand may include a large Right to Try patient pool pull-forward, risking sequential stall.
- Company remains net loss making with cash flow positivity not targeted until 2027.
- TPIP Phase 3 program could fail despite positive Phase 2b data, undermining pipeline value.
- Verona Pharma's ensifentrine could reach approval in NCFB and erode Insmed's first-in-class exclusivity.
- Hidradenitis suppurativa program for brensocatib already discontinued in April 2026 after disappointing data.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Verona Pharma | contesting | Started Phase 2 ensifentrine trial in non-CF bronchiectasis in May 2026, targeting Insmed's only approved indication |
| AstraZeneca | losing to | Original licensor of brensocatib, declined to develop it further; Insmed took it to FDA approval Aug 2025 |
| Vertex Pharmaceuticals | contesting | Dominates adjacent cystic fibrosis market while Insmed leads non-CF bronchiectasis as of 2025-2026 |
| Regeneron/Sanofi | contesting | Developing itepekimab in bronchiectasis pipeline per 2024 industry tracker, no approval yet as of mid 2026 |
Questions people ask
- Is Insmed profitable in 2026?
- Not yet. Insmed posted a Q1 2026 net loss of $0.76 per share despite revenue of $306.0 million, per its May 7, 2026 earnings release. Management targets cash flow positivity in 2027 without raising additional capital, but as of mid 2026 the company remains unprofitable on a GAAP basis.
- What is Insmed's biggest competitor?
- Verona Pharma is the closest emerging rival, having started a Phase 2 study of ensifentrine in non-CF bronchiectasis in May 2026, the same disease where Insmed's BRINSUPRI is the only approved treatment as of August 2025. AstraZeneca, Vertex, and Regeneron/Sanofi are adjacent respiratory players but have no approved competing drug yet.
- Could AI replace Insmed?
- No. Insmed's revenue depends on FDA, EMA, and MHRA approved drugs (BRINSUPRI approved August 12, 2025) plus specialty pharmacy distribution and physician prescribing, none of which AI can substitute for. Insmed uses AI internally via a Google Cloud partnership since October 2023 for efficiency, not as a product replacement.
- Is Insmed a safe company to join in 2026?
- Insmed grew headcount to roughly 1,664 to 1,700 employees by December 31, 2025, up over 30% year over year, and posted $606.42 million in FY2025 revenue, up 66.7%. With ~$1.2 billion in cash as of March 31, 2026 and two approved commercial drugs, the company appears in a growth phase rather than contraction.
- Who owns Insmed?
- Insmed is an independent, publicly traded company on Nasdaq under ticker INSM with no controlling parent; insiders own roughly 2% of shares as of June 8, 2026, per MarketBeat. The rest is held by institutional and public shareholders, with market capitalization around $23.1 billion as of July 23, 2026.
- Is Insmed's BRINSUPRI demand sustainable or a one-time bump?
- Uncertain. Q1 2026 BRINSUPRI revenue hit $207.9 million, up 44% quarter over quarter, but Yahoo Finance/Zacks reported on May 8, 2026 that 3,500 to 7,800 new patient starts came from a Right to Try or patient assistance pool, raising analyst concern that demand may have been pulled forward rather than organic.
Timeline
- 2026-07-16TPIP reports positive Phase 2b and 12 month OLE data; 2026 guidance reiterated at $1B+ BRINSUPRI, $450-470M ARIKAYCE
- 2026-05-01Verona Pharma initiates Phase 2 ensifentrine study in non-CF bronchiectasis
- 2026-04-01Insmed discontinues hidradenitis suppurativa program for brensocatib after disappointing data
- 2026-03-31Q1 2026 total revenue reaches $306.0 million, up ~230% YoY
- 2026-03-01Phase 3b ENCORE study of ARIKAYCE in MAC lung disease meets primary endpoints
- 2026-02-01UK MHRA grants marketing authorization for BRINSUPRI in NCFB
- 2025-11-01BRINSUPRI receives EU authorization
- 2025-08-12FDA approves BRINSUPRI as first and only treatment for non-CF bronchiectasis
- 2025-04-01Insmed redeems all $569.5 million of remaining 2028 convertible notes
- 2023-10-24Insmed enters multi-year generative AI collaboration with Google Cloud
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Drugs.com (2025-08-12)
- wikipedia.org (per aggregated snippet)
- stockanalysis.com (2026-06-21)
- PR Newswire (2026-05-07)
- PR Newswire (2026-07-16)
- SEC 8-K (2025-06-05)
- Yahoo Finance/Zacks (2026-05-08)
- 247wallst.com (2026-07-16)
- gurufocus.com (2026-07-23)
- stockanalysis.com (2026-07-02)
- Insmed Company page (2026-04-13)
- PR Newswire (2026-07-16)